2.
Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther. 2014; 36(11): 1489-1511 e4[DOI][PubMed]
3.
Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013; 17(6): 264[DOI][PubMed]
4. Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections.
5.
Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother. 2000; 45(1): 5-7[DOI][PubMed]
6.
Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003; 23(3): 369-73[DOI][PubMed]
7.
Rothstein E, Clancy DD. Toxicity of disulfiram combined with metronidazole. N Engl J Med. 1969; 280(18): 1006-7[DOI][PubMed]
8.
Patterson TF,
Thompson GR 3rd,
Denning DW,
Fishman JA,
Hadley S,
Herbrecht R,
et al.
Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4): 433-42[DOI][PubMed]
9.
L'Huillier AG,
Ing Lorenzini K,
Crisinel PA,
Rebsamen MC,
Fluss J,
Korff CM,
et al.
ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia. Pharmacogenomics. 2011; 12(10): 1493-501[DOI][PubMed]
10.
Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2017; 135(2): 148-60[DOI][PubMed]
11.
Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill. 2009; 14(30): 19287[PubMed]
Readers' Comments